Smac peptide potentiates TRAIL- or paclitaxel-mediated ovarian cancer cell death in vitro and in vivo

Mao,Hong  Luan; Pang,Yingxin; Zhang,Xiaolei; Yang,Fang; Zheng,Jingfang; Wang,Yu; Liu,Peishu

doi:10.3892/or.2012.2132

Smac peptide potentiates TRAIL- or paclitaxel-mediated ovarian cancer cell death in vitro and in vivo

Authors:
- Hong Luan Mao
- Yingxin Pang
- Xiaolei Zhang
- Fang Yang
- Jingfang Zheng
- Yu Wang
- Peishu Liu
View Affiliations

Affiliations: Department of Obstetrics and Gynecology, Qilu Hospital of Shandong University, Jinan, Shandong 250012, P.R. China
Published online on: November 9, 2012 https://doi.org/10.3892/or.2012.2132
Pages: 515-522

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Second mitochondria-derived activator of caspases (Smac) is a recently identified protein that is released from mitochondria in response to apoptotic stimuli and promotes apoptosis by antagonizing the inhibitor of apoptosis proteins (IAPs). Our previous study showed that ectopic overexpression of Smac sensitizes drug-resistant tumor cells to TRAIL- or paclitaxel-induced apoptosis in vitro. The present study was designed to explore the effect of the synthesized Smac N7 peptide in a human ovarian cancer cell line and xenograft model. The results showed that the single-agent Smac N7 had a non-cytotoxic effect, but it effectively enhanced TRAIL- or paclitaxel-induced inhibition of cell proliferation in a dose-dependent manner, even in TRAIL-resistant A2780 cells. When Smac N7 was combined with TRAIL or paclitaxel in treating A2780 cell tumor xenografts, synergistic anticancer effects were achieved. Furthermore, the combination therapy caused less damage in normal tissues and more apoptosis in tumor xenografts compared with TRAIL or paclitaxel alone. Increased apoptosis was associated with the downregulation of XIAP, survivin and the increased activity of caspase-3, along with an increased amount of cleaved PARP. In conclusion, this Smac N7 peptide is a promising candidate for ovarian cancer combination therapy, and Smac may be the target for the development of a novel class of anticancer drugs.

View Figures

View References

1	Lee JY, Shin JY, Kim HS, et al: Effect of combined treatment with progesterone and tamoxifen on the growth and apoptosis of human ovarian cancer cells. Oncol Rep. 27:87–93. 2012.PubMed/NCBI
2	Fesik SW: Promoting apoptosis as a strategy for cancer drug discovery. Nat Rev. 5:876–885. 2005. View Article : Google Scholar : PubMed/NCBI
3	Sayers TJ: Targeting the extrinsic apoptosis signaling pathway for cancer therapy. Cancer Immunol Immunother. 60:1173–1180. 2011. View Article : Google Scholar : PubMed/NCBI
4	Qiu W, Liu H, Sebastini A, Sun Q, Wang H, Zhang L and Yu J: An apoptosis-independent role of SMAC in tumor suppression. Oncogene. Jul 2–2012.(Epub ahead of print).
5	Fulda S and Vucic D: Targeting IAP proteins for therapeutic intervention in cancer. Nat Rev Drug Discov. 11:109–124. 2012. View Article : Google Scholar : PubMed/NCBI
6	De Almagro MC and Vucic D: The inhibitor of apoptosis (IAP) proteins are critical regulators of signaling pathways and targets for anti-cancer therapy. Exp Oncol. 34:200–211. 2012.PubMed/NCBI
7	Chai J, Du C, Wu JW, Kyin S, Wang X and Shi Y: Structural and biochemical basis of apoptotic activation by Smac/DIABLO. Nature. 406:855–862. 2000. View Article : Google Scholar : PubMed/NCBI
8	Du C, Fang M, Li Y, Li L and Wang X: Smac, a mitochondrial protein that promotes cytochrome c-dependent caspase activation by eliminating IAP inhibition. Cell. 102:33–42. 2000. View Article : Google Scholar : PubMed/NCBI
9	Liu Z, Sun C, Olejniczak ET, et al: Structural basis for binding of Smac/DIABLO to the XIAP BIR3 domain. Nature. 408:1004–1008. 2000. View Article : Google Scholar : PubMed/NCBI
10	Arnt CR, Chiorean MV, Heldebrant MP, Gores GJ and Kaufmann SH: Synthetic Smac/DIABLO peptides enhance the effects of chemotherapeutic agents by binding XIAP and cIAP1 in situ. J Biol Chem. 277:44236–44243. 2002. View Article : Google Scholar : PubMed/NCBI
11	Giagkousiklidis S, Vogler M, Westhoff MA, Kasperczyk H, Debatin KM and Fulda S: Sensitization for gamma-irradiation-induced apoptosis by second mitochondria-derived activator of caspase. Cancer Res. 65:10502–10513. 2005. View Article : Google Scholar : PubMed/NCBI
12	Rein DT, Volkmer AK, Volkmer J, et al: Systemic administration of bevacizumab prolongs survival in an in vivo model of platinum pre-treated ovarian cancer. Oncol Lett. 3:530–534. 2012.PubMed/NCBI
13	Krasner CN, Poveda A, Herzog TJ, et al: Patient-reported outcomes in relapsed ovarian cancer: Results from a randomized Phase III study of trabectedin with pegylated liposomal doxorubicin (PLD) versus PLD Alone. Gynecol Oncol. 127:161–167. 2012. View Article : Google Scholar
14	Mulier S, Claes JP, Dierieck V, et al: Survival benefit of adding Hyperthermic IntraPEritoneal Chemotherapy (HIPEC) at the different time-points of treatment of ovarian cancer: review of evidence. Curr Pharm Des. 18:3793–3803. 2012. View Article : Google Scholar
15	Mao HL, Liu PS, Zheng JF, Zhang PH, Zhou LG, Xin G and Liu C: Transfection of Smac/DIABLO sensitizes drug-resistant tumor cells to TRAIL or paclitaxel-induced apoptosis in vitro. Pharmacol Res. 56:483–492. 2007. View Article : Google Scholar : PubMed/NCBI
16	Oost TK, Sun C, Armstrong RC, et al: Discovery of potent antagonists of the antiapoptotic protein XIAP for the treatment of cancer. J Med Chem. 47:4417–4426. 2004. View Article : Google Scholar : PubMed/NCBI
17	Bianchi A, Ugazzi M, Ferrante L, Lecis D, Scavullo C, Mastrangelo E and Seneci P: Rational design, synthesis and characterization of potent, drug-like monomeric Smac mimetics as pro-apoptotic anticancer agents. Bioorg Med Chem Lett. 22:2204–2208. 2012. View Article : Google Scholar : PubMed/NCBI
18	Yang D, Zhao Y, Li AY, Wang S, Wang G and Sun Y: Smac-mimetic compound SM-164 induces radiosensitization in breast cancer cells through activation of caspases and induction of apoptosis. Breast Cancer Res Treat. 133:189–199. 2012. View Article : Google Scholar : PubMed/NCBI
19	Voelkel-Johnson C: TRAIL-mediated signaling in prostate, bladder and renal cancer. Nat Rev Urol. 8:417–427. 2011. View Article : Google Scholar : PubMed/NCBI
20	Kauntz H, Bousserouel S, Gossé F and Raul F: The flavonolignan silibinin potentiates TRAIL-induced apoptosis in human colon adenocarcinoma and in derived TRAIL-resistant metastatic cells. Apoptosis. 17:797–809. 2012. View Article : Google Scholar
21	Fandy TE, Shankar S and Srivastava RK: Smac/DIABLO enhances the therapeutic potential of chemotherapeutic drugs and irradiation, and sensitizes TRAIL-resistant breast cancer cells. Mol Cancer. 7:602008. View Article : Google Scholar
22	Boere IA and van der Burg ME: Review of dose-intense platinum and/or paclitaxel containing chemotherapy in advanced and recurrent epithelial ovarian cancer. Curr Pharm Des. 8:3741–3753. 2012. View Article : Google Scholar : PubMed/NCBI
23	Lindemann K, Christensen RD and Vergote I: First-line treatment of advanced ovarian cancer with paclitaxel/carboplatin with or without epirubicin (TEC versus TC) - a gynecologic cancer intergroup study of the NSGO, EORTC GCG and NCIC CTG. Ann Oncol. 23:2613–2619. 2012. View Article : Google Scholar : PubMed/NCBI
24	MacFarlane M, Merrison W, Bratton SB and Cohen GM: Proteasome-mediated degradation of Smac during apoptosis: XIAP promotes Smac ubiquitination in vitro. J Biol Chem. 277:36611–36616. 2002. View Article : Google Scholar : PubMed/NCBI
25	Ma L, Huang Y, Song Z, et al: Livin promotes Smac/DIABLO degradation by ubiquitin-proteasome pathway. Cell Death Differ. 13:2079–2088. 2006. View Article : Google Scholar : PubMed/NCBI
26	Fulda S, Wick W, Weller M and Debatin KM: Smac agonists sensitize for Apo2L/TRAIL- or anticancer drug-induced apoptosis and induce regression of malignant glioma in vivo. Nat Med. 8:808–815. 2002.PubMed/NCBI
27	Emeagi PU, Van Lint S, Goyvaerts C, et al: Proinflammatory characteristics of SMAC/DIABLO-induced cell death in antitumor therapy. Cancer Res. 72:1342–1352. 2012. View Article : Google Scholar : PubMed/NCBI
28	Jiang G, Zhao J, Xiao X, et al: An N-terminal Smac peptide sensitizes human prostate carcinoma cells to methyl jasmonate-induced apoptosis. Cancer Lett. 302:37–46. 2011. View Article : Google Scholar : PubMed/NCBI
29	Xiao XY, Jiang GS, Wang L, Lv L and Zeng FQ: Predominant enhancement of apoptosis induced by methyl jasmonate in bladder cancer cells: therapeutic effect of the Antp-conjugated Smac peptide. Anticancer Drugs. 22:853–863. 2011. View Article : Google Scholar : PubMed/NCBI